Readoutin 14d
Atea Pharmaceuticals, Inc. — Bemnifosbuvir-Ruzasvir
Phase 3 primary completion: C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV.
- Date
- Dec 2026
- Type
- Readout
- Indication
- HEPATITIS C VIRUS CHRONIC INFECTION